22 May 2015

Klaricid Paediatric (Clarithromycin) - United Kingdom

Klaricid Paediatric Suspension

Generic Matches for Clarithromycin (3)
Klaricid Paediatric Suspension 125mg/5ml
Klaricid Adult Sachet
Klaricid XL tablets

Last Updated on 22 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Klaricid Paediatric Suspension Indication

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid Paediatric Suspension 125mg/5ml is indicated in children 6 months to 12 years.

Klaricid Paediatric Suspension 125mg/5ml is indicated for the treatment of infections caused by susceptible organisms. Indications include:

Lower respiratory tract infections.

Upper respiratory tract infections.

Skin and skin structure infections.

Acute otitis media.

Klaricid Paediatric Suspension 125mg/5ml is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha-haemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae; Chlamydia pneumoniae.

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Klaricid Paediatric Suspension 125mg/5ml has bactericidal activity against several bacterial strains. These organisms include H. influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori and Campylobacter species.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Klaricid Paediatric Suspension Generic Name




Summary Product Characteristics (SPCs) Links
All SPC - Klaricid Paediatric Suspension (external site)
SPC - Klaricid Paediatric Suspension 125mg/5ml (external site)
SPC - Klaricid Paediatric Suspension 250mg/5ml (external site)

Related Learning Zones

Hyperammonaemia Knowledge Centre

Hyperammonaemia Knowledge Centre

The Hyperammonaemia Knowledge Centre has been developed to raise awareness of this rare yet potentially deadly condition. Using this free resource, healthcare professionals are encouraged to recognise the signs and symptoms of hyperammonaemia and begin the correct treatment immediately. Content is arranged into sections with disease awareness information, mode of action videos, first-line treatment options, links to useful external hyperammonaemia content and more… 

Type 2 Diabetes

Type 2 Diabetes

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Klaricid Paediatric Marketing Information

Klaricid Paediatric Generic Name
Marketing Company
BGP Products Ltd.
Drug Type
Date of Issue, Marketing Authority - Klaricid Paediatric Suspension 125mg/5ml: 16/10/1995

- Klaricid Paediatric Suspension 250mg/5ml: 19/05/1999

Related Drugs - Infectious Diseases

Back to top